Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis

Rheumatology

Volumn 44, Issue 5, 2005, Pages 677-680

  Bernatsky, Samy ^b   Hudson, M ^b   Suissa, S ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Congestive heart failure; DMARDs; Rheumatoid arthritis

Indexed keywords

AZATHIOPRINE; CELECOXIB; CHLORAMBUCIL; CHLOROQUINE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLD DERIVATIVE; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; ROFECOXIB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIRHEUMATIC AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DRUG USE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK REDUCTION; SEX RATIO; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; EPIDEMIOLOGY; FACTUAL DATABASE; MIDDLE AGED; MULTICENTER STUDY; NORTH AMERICA; STATISTICS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE INHIBITORS; DATABASES, FACTUAL; EPIDEMIOLOGIC METHODS; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NORTH AMERICA;

EID: 21244436822     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keh610     Document Type: Article

References (19)

1. Myllykangas-Luosujarvi R, Aho K, Kautiainen H, Isomaki H. Shortening of life span and causes of excess mortality in a population-based series of subjects with rheumatoid arthritis. Clin Exp Rheumatol 1995;13:149-53.
2. Turesson C, Jarenros A, Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: Results from a community based study. Ann Rheum Dis 2004;63:952-5.
3. Riboldi P, Gerosa M, Luzzana C, Catelli L. Cardiac involvement in systemic autoimmune diseases. Clin Rev Allergy Immunol 2002; 23:247-61.
4. del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45.
5. Tsuyuki R, Shibata M, Nilsson C, Hervas-Malo M. Contemporary burden of illness of congestive heart failure in Canada. Can J Cardiol 2003;19:436-8.
6. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: Rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004;116:305-11.
7. Suissa S, Ernst P, Kezouh A, Bitton A, Hudson M. Newer disease modifying anti-rheumatic drugs (DMARDS) and the risk of serious hepatic adverse events in rheumatoid arthritis. Am J Med 2004;117:87-92.
8. Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. In: Strom BL, ed. Pharmacoepidemiology. New York: John Wiley, 2000:785-805.
9. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002;162:1111-15.
10. Congestive heart failure in the United States: A new epidemic. National Heart, Lung, and Blood Institute National Institutes of Health Data Fact Sheet, 1996.
11. Mamdani M, Juurlink DN, Lee DS et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: A population-based cohort study. Lancet 2004;363:1751-6.
12. Whelton A, Fort JG, Puma JA et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: A randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Therapeut 2001;8:85-95.
13. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-11.
14. Reginster JY. The prevalence and burden of arthritis. Rheumatology 2002;41:3-6.
15. Walker-Bone K, Javaid K, Arden N, Cooper C. Regular review: Medical management of osteoarthritis. Br Med J 2000;321:936-40.
16. Sany J, Bourgeois P, Saraux A et al. Characteristics of patients with rheumatoid arthritis in France: A study of 1109 patients managed by hospital based rheumatologists. Ann Rheum Dis 2004;63:1235-40.
17. Jong P, Gong Y, Liu PP, Austin PC, Lee DS, Tu JV. Care and outcomes of patients newly hospitalized for heart failure in the community treated by cardiologists compared with other specialists. Circulation 2003;108:184-91.
18. American College of Rheumatology Hotline. Update on the safety of new drugs for rheumatoid arthritis. Part II: CHF, infection and other safety issues, 2003 (www.rheumatology.org).
19. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) trial. Circulation 2003;107:3133-40.